Federal Register / Vol. 70, No.
140 / Friday, July 22, 2005 / Notices
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, Intentional Single
Motherhood Among Older Women.
Date: July 27, 2005.
Time: 1 p.m. to 1:30 p.m..
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Marita R. Hopmann, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Building, Room 5B01, Bethesda, MD 20892,
(301) 435–6911, hopmannm@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: July 15, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–14501 Filed 7–21–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001
42355
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Physical
Activity and Stress.
Date: July 26, 2005.
Time: 1 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Michael Selmanoff, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3134,
MSC 7844, Bethesda, MD 20892, (301) 435–
1119, mselmanoff@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Immunotoxicity.
Date: July 27, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Stephen M. Nigida, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4212,
MSC 7812, Bethesda, MD 20892, (301) 435–
1222, nigidas@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Cancer
Immunotherapy.
Date: July 28, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Sharon K. Gubanich, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804, Bethesda, MD 20892, (301) 435–
1767, gubanics@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Behavorial
and Social Science FIRCA.
Date: July 28, 2005.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Dan D. Gerendasy, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5132,
MSC 7843, Bethesda, MD 20892, (301) 594–
6830, gerendad@csr.nih.gov.
PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\22JYN1.SGM
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Rehabilitation Sciences.
Date: July 28, 2005.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jo Pelham, BA, Scientific
Review Administrator, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 4102, MSC 7814,
Bethesda, MD 20892, (301) 435–1786,
pelhamj@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Special
Skeletal Muscle Exercise Physiology.
Date: July 29, 2005.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Richard J. Bartlett, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4110,
MSC 7814, Bethesda, MD 20892, (301) 435–
6809, bartletr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflicts—AIDS Behavioral Sciences.
Date: August 2, 2005.
Time: 10 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Ranga V. Srinivas, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5222,
MSC 7852, Bethesda, MD 20892, (301) 435–
1167, srinivar@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Neurogenesis and Development.
Date: August 2, 2005.
Time: 1 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Joanne T Fujii, PhD,
Scientific Review Administrator, Center for
22JYN1
 42356 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5204,
MSC 7850, Bethesda, MD 20892, (301) 435–
1178, fujiij@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Technology
for DNA Analysis.
Date: August 3, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Sally Ann Amero, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4190,
MSC 7849, Bethesda, MD 20892, (301) 435–
1159, ameros@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Neurogenesis Special Interest Panel.
Date: August 4, 2005.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Michael A. Lang, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4140,
MSC 7850, Bethesda, MD 20892, (301) 435–
1265, langm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Genetic
Basis for Psychiatric Diseases.
Date: August 8, 2005.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: David J. Remondini, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2210,
MSC 7890, Bethesda, MD 20892, (301) 435–
1038, remondid@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Pain
Studies.
Date: August 8, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: J. Terrell Hoffeld, PhD,
DDS, Dental Officer, USPHS, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4116,
MSC 7816, Bethesda, MD 20892, (301) 435–
1781, hoffeldt@csr.nih.gov.
VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Neuronal
Calcium Signaling.
Date: August 11, 2005.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Peter B. Guthrie, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7850, Bethesda, MD 20892, (301) 435–
1239, guthriep@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Molecular
Mechanisms of Neurodegeneration.
Date: August 15, 2005.
Time: 4 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Toby Behar, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4136,
MSC 7850, Bethesda, MD 20892, (301) 435–
4433, behart@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clincial Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 15, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–14494 Filed 7–21–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of HIV-Dependent
Expression Constructs and Uses
Therefor for the Development of FDA-
Approvable HIV Diagnostic Kits
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license to practice the invention
embodied in PCT/US04/31967 filed
September 28, 2004 from U.S.
provisional application 60/507,034 (E–
276–2003/0–US–01), entitled ‘‘HIV-
Dependent Expression Constructs and
PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\22JYN1.SGM
Uses Therefor’’ (E–276–2003/0–PCT–
02), (Inventors: Yuntao Wu and Jon
Marsh), to Revix Technology LLC
(hereafter Revix), having a place of
business in Manassas, Virginia. The
patent rights in these inventions have
been assigned to the United States of
America.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
September 20, 2005 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Sally Hu, Ph.D., M.B.A., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
E-mail: hus@mail.nih.gov; Telephone:
(301) 435–5606; Facsimile: (301) 402–
0220.
SUPPLEMENTARY INFORMATION: E–276–
2003/0–PCT–02 provides nucleic acid
molecules comprising expressible
sequences, which could be reporter or
therapeutic genes, whose expression
depends on the presence of HIV Tat and
Rev proteins. This invention could be
used for detection of HIV infection, in
screening assays to identify compounds
that inhibit HIV infection, and
potentially as a therapeutic to kill HIV-
infected cells and treat HIV-infected
subjects.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
The field of use may be limited to the
development of FDA-approvable HIV
clinical diagnostic kit.
It has to be noted that the non-
exclusive license opportunities in the
field(s) of use of the development of HIV
detection kit/reagent for research use
and/or cellular screening method for
research use, as well as the exclusive
license opportunity in the field of use of
the development of a novel therapeutic
against HIV infections are still available
for subject invention.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
22JYN1